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The study of Noori et al.
1 in this issue, brings together two of the
major unresolved therapeutic issues in preterm neonatology, how
much oxygen to give them and how to treat the patent ductus
arteriosus. Oxygen saturations in the low 90s were accepted by most
of us as appropriate for preterm babies until the publication of the
observational study of Tin et al.,
2 in 2001 from the north of
England. This study used different neonatal intensive care unit
(NICU) policies to show a markedly lower rate of retinopathy of
prematurity needing cryotherapy between babies with saturations
targeted between 70 and 90% and those targeted between 88 and
98% (6 vs 27%) with no difference in mortality. The study of Noori
et al.
1 adds further consistency to the reductions in treated
retinopathy of prematurity rates that have now been shown in
several ‘before and after’ studies around a change in an NICU
saturation targeting protocol.
3,4 Noori et al.’s study
1 shows a
reduction of treated retinopathy of prematurity from 34 to 9%,
4 years either side of a change in oxygen saturation limits from
89–94% to 83–89% in two NICUs in Los Angeles. The
observational data with respect to the premature eye are becoming
quite compelling buty(and there’s always a ‘but’), what is good
for one organ may not be good for other organs. Two of the organs
whose normal function may be very dependent on oxygen levels
are the brain and the closure of the ductus arteriosus.
Noori et al.’s study
1 explores the latter of these by comparing
the incidence of what they term as haemodynamically signiﬁcant
patent ductus arteriosus (PDA) in the two epochs either side of the
change in oxygen policy. They show a statistically signiﬁcant but
probably not clinically signiﬁcant increase in incidence from 63 to
75% with no signiﬁcant difference in ligation rate (24 vs 30%).
PDA is a difﬁcult outcome because it depends how you look for it
and, if you look echocardiographically, how you measure
signiﬁcance. The protocol in this study involved echocardiography
within the ﬁrst 24h, with a 1.0mm diameter being used as a
threshold for haemodynamic signiﬁcance and treatment. This is
quite a low threshold (a 1.0mm duct is quite well constricted) and
this reﬂects in a high incidence and treatment rate. Although there
is no consensus, diameters between 1.5 and 2.0mm are more
commonly used in very preterm babies as cut offs for
haemodynamic signiﬁcance. In our own work, pulmonary to
systemic ﬂow ratios did not rise until ducts were over 1.5mm in
diameter and consistently so when over 2mm.
5 Notwithstanding
this, the same criteria were applied in each time period in the
Noori’s study
1 and there was a small rise in the incidence. There was
also an increase in ligation rate but this did not reach statistical
signiﬁcance. However, to my non-North American eyes, the surgical
ligation rates in both time periods are very high. To compare with
my local data, in 2003 to 2006 inclusive, the median rate of PDA
ligation in babies <1000g in the eight perinatal NICUs in New
South Wales, Australia was 7.3% with a range from 4.6 to 15.9%
(Source: NSW NICUS data collection). Either we, ‘Down Under’, are
missing something or there are a lot of babies on the other side of
the Paciﬁc having unnecessary chest surgery. Like many aspects of
PDA therapy, this badly needs testing in a clinical trial, particularly
in light of the associations described from the trial of indomethacin
prophylaxis in preterms (TIPP) trial between ductal ligation and
worse pulmonary, retinal and 18-month neurosensory outcomes.
6
The targeted early approach to medical PDA therapy used in this
study has much theoretical merit but is also untested. We are
testing this in the DETECT trial, which is currently recruiting in
three Australian centers. In this trial, babies born before 29 weeks
have echocardiography within the ﬁrst 12h and those with poorly
constricting ducts (thresholds 1.2 to 2.0mm depending on
postnatal age) are blindly randomised to indomethacin or placebo.
Hopefully, the results of this study will give better guidance to the
value of an early targeted approach.
Despite these therapeutic uncertainties about the ductus, Noori
et al.
1 showed only small increases in PDA as deﬁned in this study
with lower oxygen saturation targeting. Although this is reassuring,
the trend is there and, with greater statistical power, this might
become more signiﬁcant. The other remaining uncertainty about
lower oxygen targeting is the impact on the developing brain. The
original observational study of Tin et al.
2 is, to my knowledge, the
only one that has looked at neurodevelopmental outcome. This
study showed no differences in cerebral palsy rates at 1 year in
babies whose oxygen saturations were targeted lower. This is an
important observation but not an outcome or study design with
which to conﬁrm safety, so this uncertainty about the impact of
lower oxygen targeting on the brain remains. To go to that
well-worn clinical epidemiological conclusionymore research is
needed. However, with this I do not have to leave you in the usual
evidence-based vacuum because this research is happening. In an
unprecedented international collaboration, several large and
similarly designed trials are underway: BOOST 2 (Australia),
BOOST UK and BOOST NZ, the Canadian Oxygen Trial and US
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perennial question of how much oxygen to give these most
vulnerable babies is to join one of these trials.
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